Eledon Pharmaceuticals (ELDN) Expected to Post Earnings on Friday

Eledon Pharmaceuticals (NASDAQ:ELDN) is anticipated to issue its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11).

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ ELDN opened at $2.67 on Thursday. Eledon Pharmaceuticals has a one year low of $1.35 and a one year high of $4.49. The business’s 50-day moving average price is $2.59 and its two-hundred day moving average price is $3.11. The company has a market capitalization of $216.96 million, a P/E ratio of -2.93 and a beta of 0.95.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wall Street Zen lowered Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, August 23rd. Weiss Ratings upgraded Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday. Finally, Rodman & Renshaw assumed coverage on Eledon Pharmaceuticals in a report on Tuesday, July 21st. They issued a “buy” rating and a $12.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that selectively modulate the immune system for patients with life-threatening diseases. The company’s research is centered on conditions involving immune activation, including organ transplantation, autoimmune disorders and other inflammatory diseases. Eledon’s lead product candidate is tegoprubart, a monoclonal antibody designed to block CD40 ligand, a protein involved in immune-system signaling.